Suzetrigine Is Not Expected to Have Clinically Relevant DDIs with Apixaban and Rivaroxaban Based on PBPK Modeling
Abstract
Suzetrigine (VX-548) is a first-in-class, oral, non-opioid, FDA-approved analgesic for the treatment of moderate to severe acute pain. Based on Phase 1 clinical drug-drug interaction (DDI) studies, suzetrigine is a weak-to-moderate cytochrome P450 3A (CYP3A) inducer and thus has the potential to decrease exposure and impact efficacy of CYP3A substrates, such as apixaban and rivaroxaban, which are commonly used as anticoagulants peri- and post-operatively. Given this, it is important to assess the DDIs of apixaban and rivaroxaban with suzetrigine. Physiologically based pharmacokinetic (PBPK) models are commonly used to assess DDIs mediated through modulation of CYP3A and were used here to quantify the potential effect of co-administration of suzetrigine on apixaban and rivaroxaban PK. The PBPK models were validated using observed data from suzetrigine, apixaban, and rivaroxaban clinical DDI studies. The validated models predict that suzetrigine decreases apixaban AUCinf by 6.1% (90% confidence interval [CI]: 5.7% to 6.4%) and Cmax by 1.8% (90% CI: 1.7% to 1.9%), and rivaroxaban AUCinf by 8.4% (90% CI: 7.2% to 9.6%) and Cmax by 3.5% (90% CI: 3.3% to 3.7%). The predicted small reductions in apixaban and rivaroxaban exposures (AUCinf <10%) are not expected to be clinically relevant since a 20% no-effect boundary is typically used to determine the clinical impact of a DDI. The PBPK model predictions are consistent with the apixaban and rivaroxaban labels, which do not warn…
Read the paper
Related studies
- Noninvasive and Point-of-Care Surface-Enhanced Raman Scattering (SERS)-Based Breathalyzer for Mass Screening of Coronavirus Disease 2019 (COVID-19) under 5 min
- De Novo Transcriptome Analysis and Detection of Antimicrobial Peptides of the American Cockroach Periplaneta americana (Linnaeus)
- Molecular Characterization and Expression Profiling of Tomato GRF Transcription Factor Family Genes in Response to Abiotic Stresses and Phytohormones
- Assembly of Tight Junction Strands: Claudin-10b and Claudin-3 Form Homo Tetrameric Building Blocks that Polymerise in a Channel-Independent Manner
- Update of the Pompe variant database for the prediction of clinical phenotypes: Novel disease‐associated variants, common sequence variants, and results from newborn screening
- Machine Learning-Based SERS Chemical Space for Two-Way Prediction of Structures and Spectra of Untrained Molecules
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.